<DOC>
	<DOCNO>NCT01803555</DOCNO>
	<brief_summary>The primary objective study establish whether budesonide/formoterol fumarate dihydrate ( BF ) SPIROMAX 160/4.5 mcg effective SYMBICORT TURBOHALER 200/6 mcg administer twice daily patient persistent asthma .</brief_summary>
	<brief_title>Efficacy Safety Evaluation Budesonide/Formoterol SPIROMAX® Inhalation Powder Versus SYMBICORT® TURBOHALER®</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Informed consent/assent : For adult patient , write informed consent sign dated patient conduct study related procedure ; minor patient , write informed consent sign dated parent/legal guardian write assent sign dated patient conduct study related procedure . Male female patient 12 year old screen visit . Male female patient 18 year old , screen visit , country local regulation regulatory status study medication permit enrollment adult patient . General good health , free concomitant condition treatment could interfere study conduct , influence interpretation study observations/results , put patient increase risk study . Asthma Diagnosis : The asthma diagnosis must accordance Global Initiative Asthma ( GINA ) . Other criterion apply . History lifethreatening asthma , define protocol asthma episode require intubation and/or associate hypercapnea , respiratory arrest hypoxic seizure . Culturedocumented suspected bacterial viral infection upper low respiratory tract , sinus , middle ear resolve within 2 week screen visit . In addition , patient must exclude infection occurs screen visit baseline visit . Any asthma exacerbation require oral corticosteroid within one month screen visit . A patient must hospitalize asthma within 6 month screen visit . Presence glaucoma , cataract , ocular herpes simplex , malignancy basal cell carcinoma . Historical current evidence clinically significant disease include , limited : cardiovascular condition ( eg , congestive heart failure , know aortic aneurysm , clinically significant cardiac arrhythmia coronary heart disease ) , hepatic , renal , hematological , neuropsychological , endocrine condition ( eg , uncontrolled diabetes mellitus , uncontrolled thyroid disorder , Addison 's disease , Cushing 's syndrome ) , gastrointestinal condition ( eg , poorlycontrolled peptic ulcer , gastroesophageal reflux disease [ GERD ] ) , pulmonary condition ( eg , chronic bronchitis , emphysema , bronchiectasis need treatment , cystic fibrosis , bronchopulmonary dysplasia , chronic obstructive pulmonary disease ) . Significant defined disease , opinion investigator , would put safety patient risk participation , could affect efficacy safety analysis disease/condition become exacerbated study . Other criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Budesonide/Formoterol SPIROMAX®</keyword>
	<keyword>SYMBICORT® TURBOHALER®</keyword>
	<keyword>Asthma</keyword>
</DOC>